We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    BABYDIET
Previous Study | Return to List | Next Study

BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01115621
Recruitment Status : Unknown
Verified April 2010 by Institut fur Diabetesforschung, Munich, Germany.
Recruitment status was:  Active, not recruiting
First Posted : May 4, 2010
Last Update Posted : May 4, 2010
Sponsor:
Information provided by:
Institut fur Diabetesforschung, Munich, Germany

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The major goals of this project are to determine whether primary intervention through delayed introduction of dietary gluten is feasible and could reduce the incidence of islet autoimmunity in high-risk first degree relatives of patients with type 1 diabetes.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Other: Glutenfree diet during the first year of life Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk
Study Start Date : February 2001
Actual Primary Completion Date : December 2009
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Glutenfree diet
Glutenfree diet during the first year of life
 Other: Glutenfree diet during the first year of life
Glutenfree diet during the first year of life
No Intervention: Control - normal diet


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Effect of dietary intervention on the development of islet autoantibodies [ Time Frame: 3 years ]
    Primary outcome is to compare the prevalence of iselt autoantibodies between children participating in the dietary intervention and the control group.


Secondary Outcome Measures :
  1. Effect of dietary intervention on the development of Type 1 diabetes. [ Time Frame: 10 years ]
    Secondary outcome is to compare the prevalence of type 1 diabetes between children participating in the dietary intervention and the control group


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 3 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Newborn offspring or siblings of patients with type 1 diabetes with a HLA genotype conferring a high diabetes risk

Exclusion Criteria:

  • If infants have an illness or birth defect that precludes long-term follow-up or involves use of treatment that may alter the natural history of diabetes
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01115621


Locations
Layout table for location information
Germany
Institut für Diabetesforschung
München, Germany, 80804
Sponsors and Collaborators
Institut fur Diabetesforschung, Munich, Germany
Investigators
Layout table for investigator information
Principal Investigator: Anette G Ziegler, MD Institut für Diabetesforschung, München, Germany
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Other Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Prof. Dr. Anette-G. Ziegler, Institut fuer Diabetesforschung, Ingolstädter Landstr. 1, Neuherberg
ClinicalTrials.gov Identifier: NCT01115621    
Other Study ID Numbers: ZI310/14-1
First Posted: May 4, 2010    Key Record Dates
Last Update Posted: May 4, 2010
Last Verified: April 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
 Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases